Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis…

By Allen J. Taylor, L. Sullenberger, H. J. Lee, Jeannie K. Lee, K. Grace. Circulation, 2004

927 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/a6b4ff57caaf5a4ca77628defa4b537bf50c67d0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Chapman
2. A. Kontush

In Endocrinology, Diabetes and Metabolism

1. J. Chapman
2. A. Kontush

In Surgery

1. J. Chapman
2. A. Kontush

Citations in the corpus

• Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). (2007, background): “In patients with PAD, niacin has been associated with regression of femoral atherosclerosis and reduced progression of coronary atherosclerosis.(45,46) Whether fibrates and/or niacin will reduce the progression of peripheral atherosclerosis or reduce the risk of systemic cardiovascular events in pat”
• Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “%) levels among individuals with established CHD and moderately low HDL-C (Taylor et al., 2004).”